CN113308539A - Product for diagnosing alzheimer's disease - Google Patents
Product for diagnosing alzheimer's disease Download PDFInfo
- Publication number
- CN113308539A CN113308539A CN202110826207.4A CN202110826207A CN113308539A CN 113308539 A CN113308539 A CN 113308539A CN 202110826207 A CN202110826207 A CN 202110826207A CN 113308539 A CN113308539 A CN 113308539A
- Authority
- CN
- China
- Prior art keywords
- disease
- alzheimer
- biomarker
- expression level
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 48
- 239000000090 biomarker Substances 0.000 claims abstract description 37
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 16
- 239000000523 sample Substances 0.000 claims description 20
- 102100028348 60S ribosomal protein L26 Human genes 0.000 claims description 11
- 101001080179 Homo sapiens 60S ribosomal protein L26 Proteins 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000011156 evaluation Methods 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 238000004364 calculation method Methods 0.000 claims description 6
- 238000004891 communication Methods 0.000 claims description 6
- 101100471081 Caenorhabditis elegans rpl-31 gene Proteins 0.000 claims description 4
- 238000005094 computer simulation Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 238000003766 bioinformatics method Methods 0.000 claims description 2
- 238000012165 high-throughput sequencing Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 11
- 238000013211 curve analysis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 16
- 201000003478 cholangiolocellular carcinoma Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 102100023777 60S ribosomal protein L31 Human genes 0.000 description 6
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 description 6
- 101001113162 Homo sapiens 60S ribosomal protein L31 Proteins 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 102100022681 40S ribosomal protein S27 Human genes 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100196597 Caenorhabditis elegans rpl-26 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002986 genetic algorithm method Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/10—Complex mathematical operations
- G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Data Mining & Analysis (AREA)
- Medical Informatics (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Theoretical Computer Science (AREA)
- Computational Mathematics (AREA)
- Mathematical Analysis (AREA)
- Evolutionary Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Mathematical Physics (AREA)
- Biophysics (AREA)
- Pure & Applied Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Microbiology (AREA)
- Software Systems (AREA)
- Mathematical Optimization (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioethics (AREA)
Abstract
Products for diagnosing Alzheimer's disease are disclosed, the products comprising reagents for detecting the expression level of a combination of biomarkers in a sample. ROC curve analysis shows that the biomarker combinations of the present invention have higher AUC values. According to the research results of the present invention, the biomarker combinations of the present invention can be applied to the diagnosis of alzheimer's disease.
Description
Technical Field
The invention belongs to the field of biological medicines, and relates to a product for diagnosing Alzheimer disease.
Background
Alzheimer Disease (AD) is a progressive neurodegenerative Disease with occult onset of Disease. Clinically, the overall dementia such as dysmnesia, aphasia, disuse, agnosia, impairment of visual spatial skills, dysfunction in execution, and personality and behavior changes are characterized, and the etiology is unknown. Patients who are older than 65 years are called presenile dementia; the patient after 65 years old is called senile dementia. Patients can usually survive 8 to 10 years after symptoms appear, but the course of the disease can be 1 to 25 years. Death is usually caused by pneumonia, malnutrition or general physical consumption (activity). In 2015, the number of global dementia patients reaches 4680 million, 50% -75% of them are alzheimer patients, about 990 million new dementia patients will be diagnosed, and 1 new person is increased every 3 seconds on average, and 1.31 million persons will be predicted by 2050. Studies have shown that senile dementia is the fourth leading cause of death in the elderly following tumors, heart disease, cerebrovascular disease, and is spent the third in all diseases. With the aging of the population in China, the number of Alzheimer's disease patients is continuously increasing. At present, about 600 thousands of patients exist in China, the number of the patients is the first of the world, and 30 thousands of new cases exist in each year, so that the traditional Chinese medicine is one of the countries with the fastest global acceleration. Alzheimer's disease may be a heterogeneous group of diseases involving many factors, such as genetics, trauma, viral infection, other diseases, etc., but the pathogenesis of alzheimer's disease is not clear, wherein one of the main mechanisms is that β -secretase l (β -site amyloid accusor protein-cleavangenzyme, BACE1) cleaves amyloid plaques formed by amyloid preproprotein (APP) to aggregate in neurons, breaking the equilibrium state of Α β 42/Α β 40, and generating neurotoxicity.
AD and other types of dementia, such as vascular dementia (VaD), Parkinson's Disease Dementia (PDD), behavioral variability frontotemporal dementia (bvFTD), lewy body Dementia (DLB), etc., may have overlapping clinical manifestations, pathology and biomarkers, often leading to difficulties in clinical diagnosis. Based on the above problems, clinical treatment of AD requires an effective method for diagnosing AD.
Disclosure of Invention
The invention provides a biomarker combination, wherein the biomarker comprises LOC653658, CLC, RPL26 and RPL 31.
The invention also provides the application of the detection reagent of the biomarker combination in the preparation of products for diagnosing Alzheimer disease.
In the present invention, the term "biomarker" means a compound, preferably a gene, which is differentially present (i.e. increased or decreased) in a biological sample from a subject or a group of subjects having a first phenotype (e.g. having a disease) compared to a biological sample from a subject or a group of subjects having a second phenotype (e.g. no disease). The term "biomarker" generally refers to the presence/concentration/amount of one gene or the presence/concentration/amount of two or more genes.
The term "subject" means any animal, also human and non-human animals. The term "non-human animal" includes all vertebrates, e.g., mammals, such as non-human primates (particularly higher primates), sheep, dogs, rodents (such as mice or rats), guinea pigs, goats, pigs, cats, rabbits, cattle, and any domestic or pet animal; and non-mammals, such as chickens, amphibians, reptiles, and the like.
Biomarkers can be differentially present at any level, but are typically present at levels that are increased by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, or more; or generally at a level that is reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% (i.e., absent).
Preferably, the biomarkers are differentially present at levels of statistical significance (i.e., p-value less than 0.05 and/or q-value less than 0.10, as determined using the Welch's T-Test or the Wilcoxon rank-sum Test.
Further, the reagent comprises a primer, a probe and an antibody.
The term "primer" refers to 7 to 50 nucleic acid sequences capable of forming a base pair (base pair) complementary to a template strand and serving as a starting point for replication of the template strand. The primers are generally synthesized, but naturally occurring nucleic acids may also be used. The sequence of the primer does not necessarily need to be completely identical to the sequence of the template, and may be sufficiently complementary to hybridize with the template. Additional features that do not alter the basic properties of the primer may be incorporated. Examples of additional features that may be incorporated include, but are not limited to, methylation, capping, substitution of more than one nucleic acid with a homolog, and modification between nucleic acids.
The term "nucleic acid" broadly refers to: a segment of a chromosome; fragments or portions of DNA, cDNA and/or RNA. Nucleic acids can be obtained or obtained from a nucleic acid sample that is initially separated from any source (e.g., isolated from, purified from, amplified from, cloned or reverse transcribed from sample DNA or RNA).
The term "probe" refers to a molecule that binds to a specific sequence or subsequence or other portion of another molecule. Unless otherwise indicated, the term "probe" generally refers to a polynucleotide probe that is capable of binding to another polynucleotide (often referred to as a "target polynucleotide") by complementary base pairing. Depending on the stringency of the hybridization conditions, a probe can bind to a target polynucleotide that lacks complete sequence complementarity to the probe. The probe may be directly or indirectly labeled, and includes within its scope a primer. Hybridization modes include, but are not limited to: solution phase, solid phase, mixed phase or in situ hybridization assays.
The invention also provides a product for diagnosing Alzheimer's disease, which comprises a reagent for detecting the gene expression level of the biomarker combination in a sample.
Further, the product comprises a kit, a chip or a test strip.
Further, the reagent comprises a reagent for detecting the expression level of the biomarker combination by PCR, in situ hybridization, a chip, a high-throughput sequencing platform or an immunoassay, preferably, the PCR comprises reverse transcription PCR or real-time quantitative PCR.
In the present invention, the kit further comprises a container, instructions for use, a positive control, a negative control, a buffer, an auxiliary agent or a solvent, and instructions for use with the kit, wherein the instructions describe how to use the kit for detection, and how to use the detection results to determine the development of a disease and select a treatment regimen.
The kit of the present invention may contain a plurality of different reagents suitable for practical use (e.g., for different detection methods), and is not limited to the reagents listed so far, and is included in the scope of the present invention as long as the reagent diagnoses alzheimer's disease based on the detection of the biomarker combination described above.
Further, the product also comprises reagents for processing the sample.
The invention also provides the use of a biomarker for constructing a computational model for predicting alzheimer's disease or a system incorporating said computational model, said biomarker comprising the biomarker combination according to claim 1;
preferably, the calculation model takes the expression level of the biomarker as an input variable, and outputs the risk probability of the disease by performing operation through a bioinformatics method.
As the skilled person will be aware, the step of associating a marker level with a certain likelihood or risk may be carried out and carried out in different ways. Preferably, the measured concentrations of the marker and one or more other markers are mathematically combined and the combined value is correlated to the underlying diagnostic problem. The determination of marker values may be combined by any suitable prior art mathematical method.
Preferably, the mathematical algorithm applied in the marker combination is a logarithmic function. Preferably, the result of applying such a mathematical algorithm or such a logarithmic function is a single value. Such values can be easily correlated, for example, to an individual's risk for alzheimer's disease or to other diagnostic purposes of interest that are helpful in assessing alzheimer's patients, in light of underlying diagnostic problems. In a preferred manner, such a logarithmic function is obtained as follows: a) classifying individuals into groups, e.g., normal persons, individuals at risk of alzheimer's disease, patients with alzheimer's disease, etc., b) identifying markers that differ significantly between these groups by univariate analysis, c) logarithmic regression analysis to assess independent difference values of the markers that can be used to assess these different groups, and d) constructing a logarithmic function to combine the independent difference values. In this type of analysis, the markers are no longer independent, but represent a combination of markers.
The logarithmic function used to correlate marker combinations with disease preferably employs algorithms developed and obtained by applying statistical methods. For example, suitable statistical methods are Discriminant Analysis (DA) (i.e., linear, quadratic, regular DA), Kernel methods (i.e., SVM), nonparametric methods (i.e., k-nearest neighbor classifiers), PLS (partial least squares), tree-based methods (i.e., logistic regression, CART, random forest methods, boosting/bagging methods), generalized linear models (i.e., logistic regression), principal component-based methods (i.e., SIMCA), generalized additive models, fuzzy logic-based methods, neural network-and genetic algorithm-based methods. The skilled person will not have problems in selecting a suitable statistical method to evaluate the marker combinations of the invention and thereby obtain a suitable mathematical algorithm.
The present invention also provides a system, comprising:
(1) an Alzheimer's disease assessment apparatus including a control unit and a storage unit for assessing whether a subject has Alzheimer's disease; and
(2) information communication terminal devices communicatively connected to each other, which provide data on gene expression levels of the aforementioned biomarker combinations in a sample from a subject;
wherein the control unit of the Alzheimer's disease assessment apparatus comprises:
1) a data receiving unit that receives data on expression levels of the aforementioned biomarker combinations of the sample transmitted from the information communication terminal device;
2) a discrimination value calculation unit that calculates a discrimination value based on the discrimination of the expression level of the aforementioned biomarker combination in the sample received by the data reception unit and the expression level of the aforementioned biomarker combination having the explanatory variable stored in the storage unit;
3) a discrimination value criterion evaluation unit that evaluates the condition of alzheimer's disease in the subject based on the discrimination value calculated by the discrimination value calculation unit; and
4) an evaluation result transmitting unit that transmits the evaluation result of the subject obtained by the discrimination value reference evaluation unit to the information communication terminal device.
The invention also provides the application of the biomarker combination in screening candidate drugs for treating Alzheimer disease.
The invention has the following advantages and beneficial effects:
the invention discovers for the first time that whether a subject suffers from Alzheimer disease can be predicted or diagnosed by detecting the expression levels of LOC653658, CLC, RPL26 and RPL 31.
LOC653658 Gene ID in NCBI 653658.
Gene ID 1178 of CLC in NCBI.
Gene ID 6154 of RPL26 in NCBI.
Gene ID 6160 of RPL31 in NCBI.
LOC650276 Gene ID:650276 in NCBI, also known as RPL7P6, Gene ID: 90193.
Gene ID 6232 of RPS27 in NCBI.
Drawings
FIG. 1 shows the ROC plot of LOC653658 for the diagnosis of Alzheimer's disease;
FIG. 2 shows ROC plots for CLC diagnosis of Alzheimer's disease;
FIG. 3 shows a ROC plot of RPL26 for diagnosis of Alzheimer's disease;
FIG. 4 shows a ROC plot of RPL31 diagnosis of Alzheimer's disease;
FIG. 5 shows the ROC plot of LOC650276 for diagnosing Alzheimer's disease;
FIG. 6 shows a ROC plot of RPS27 diagnosis of Alzheimer's disease;
FIG. 7 shows ROC plots for the joint diagnosis of Alzheimer's disease by LOC653658, CLC, RPL26 and RPL 31;
FIG. 8 shows ROC plots for the combined diagnosis of Alzheimer's disease by CLC, LOC650276, RPS27, RPL 26.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings and examples. The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention.
Example 1 screening of differentially expressed genes associated with Alzheimer's disease
GSE63060 is downloaded from a GEO database, and is subjected to difference analysis by using an R language edgeR package to obtain 69 differentially expressed genes, wherein the screening standard is as follows: pvaluel <0.05, | logFC | > 0.5.
GSE63060 data set control AD 104:145 (population ratio)
Among them, LOC653658, CLC, RPL26, RPL31, LOC650276, RPS27 genes were significantly down-regulated in the blood level of alzheimer patients compared to normal controls, with the difference having statistical significance (P value <0.05), and the results are shown in fig. 1A, fig. 2A, fig. 3A, fig. 4A, fig. 5A, fig. 6A.
Example 2 diagnostic Performance validation
Receiver Operating Curves (ROCs) were plotted using the R package "pROC" (version 1.15.0), AUC values, sensitivity and specificity were analyzed, and the diagnostic efficacy of the markers alone or in combination was judged. When the diagnosis efficiency of the index combination is judged, logistic regression is carried out on the expression level of each gene, the probability of whether each individual suffers from cancer is calculated through a fitted regression curve, different probability division threshold values are determined, and the sensitivity, specificity, accuracy and the like of the combined detection scheme are calculated according to the determined probability division threshold values. The single gene and multiple gene combined diagnostic potency data are shown in table 1 and fig. 1B, 2B, 3B, 4B, 5B, 6B, 7, 8.
TABLE 1 diagnostic efficacy
Gene | AUC value |
LOC653658 | 0.772 |
CLC | 0.670 |
RPL26 | 0.755 |
RPL31 | 0.700 |
LOC650276 | 0.724 |
RPS27 | 0.701 |
LOC653658+CLC+RPL26+RPL31 | 0.822 |
CLC+LOC650276+RPS27+RPL26 | 0.753 |
According to experimental results, the diagnosis effect of the combination of LOC653658, CLC, RPL26 and RPL31 on Alzheimer disease is better than that of a single marker, and the diagnosis effect is better.
The description of the embodiments is only intended to serve for understanding the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
Claims (10)
1. A biomarker combination, wherein the biomarkers comprise LOC653658, CLC, RPL26 and RPL 31.
2. Use of a detection reagent of the biomarker combination according to claim 1 in the preparation of a product for diagnosing alzheimer's disease.
3. The use of claim 2, wherein said reagents comprise primers, probes, antibodies.
4. A product for diagnosing alzheimer's disease comprising reagents for detecting the gene expression level of the biomarker panel of claim 1 in a sample.
5. The product of claim 4, wherein the product comprises a kit, chip or strip.
6. The product of claim 4, wherein the reagents comprise reagents for detecting the expression level of the biomarker combinations by PCR, in situ hybridization, chip, high throughput sequencing platform, or immunoassay, preferably wherein the PCR comprises reverse transcription PCR or real time quantitative PCR.
7. A product according to any of claims 4 to 6, further comprising reagents for processing the sample.
8. Use of a biomarker for constructing a computational model for predicting alzheimer's disease or a system incorporating said computational model, wherein said biomarker comprises the biomarker panel of claim 1;
preferably, the calculation model takes the expression level of the biomarker as an input variable, and outputs the risk probability of the disease by performing operation through a bioinformatics method.
9. A system, comprising:
(1) an Alzheimer's disease assessment apparatus including a control unit and a storage unit for assessing whether a subject has Alzheimer's disease; and
(2) information communication terminal devices communicatively connected to each other, which provide data on the gene expression level of the biomarker combination according to claim 1 in a sample from a subject;
wherein the control unit of the Alzheimer's disease assessment apparatus comprises:
1) a data receiving unit that receives data on the expression level of the biomarker combination according to claim 1 for the sample transmitted from the information communication terminal device;
2) a discrimination value calculation unit that calculates a discrimination value based on discrimination of an expression level of the biomarker combination of claim 1 in the sample received by the data reception unit and an expression level of the biomarker combination of claim 1 with an explanatory variable stored in the storage unit;
3) a discrimination value criterion evaluation unit that evaluates the condition of alzheimer's disease in the subject based on the discrimination value calculated by the discrimination value calculation unit; and
4) an evaluation result transmitting unit that transmits the evaluation result of the subject obtained by the discrimination value reference evaluation unit to the information communication terminal device.
10. Use of the biomarker combination according to claim 1 for screening a candidate drug for the treatment of alzheimer's disease.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310273144.3A CN116219002A (en) | 2021-07-21 | 2021-07-21 | Biomarker combination and application thereof |
CN202110826207.4A CN113308539A (en) | 2021-07-21 | 2021-07-21 | Product for diagnosing alzheimer's disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110826207.4A CN113308539A (en) | 2021-07-21 | 2021-07-21 | Product for diagnosing alzheimer's disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310273144.3A Division CN116219002A (en) | 2021-07-21 | 2021-07-21 | Biomarker combination and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113308539A true CN113308539A (en) | 2021-08-27 |
Family
ID=77382315
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110826207.4A Pending CN113308539A (en) | 2021-07-21 | 2021-07-21 | Product for diagnosing alzheimer's disease |
CN202310273144.3A Pending CN116219002A (en) | 2021-07-21 | 2021-07-21 | Biomarker combination and application thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310273144.3A Pending CN116219002A (en) | 2021-07-21 | 2021-07-21 | Biomarker combination and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN113308539A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114999656A (en) * | 2022-07-27 | 2022-09-02 | 苏州药明泽康生物科技有限公司 | Alzheimer disease risk assessment system and module |
CN117711616A (en) * | 2023-11-23 | 2024-03-15 | 北京爱思益普生物科技股份有限公司 | Alzheimer's prediction model establishment method and system based on gene expression data |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120232016A1 (en) * | 2011-03-08 | 2012-09-13 | Coleman Paul D | Method and system to detect and diagnose alzheimer's disease |
US20140315736A1 (en) * | 2011-07-12 | 2014-10-23 | Rowan University | Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease |
US20150141491A1 (en) * | 2012-07-11 | 2015-05-21 | The University Of Birmingham | Therapeutic Targets for Alzheimer's Disease |
CN109576362A (en) * | 2018-12-28 | 2019-04-05 | 北京泱深生物信息技术有限公司 | Alzheimer diagnosis and treatment marker FAM170A |
-
2021
- 2021-07-21 CN CN202110826207.4A patent/CN113308539A/en active Pending
- 2021-07-21 CN CN202310273144.3A patent/CN116219002A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120232016A1 (en) * | 2011-03-08 | 2012-09-13 | Coleman Paul D | Method and system to detect and diagnose alzheimer's disease |
US20140315736A1 (en) * | 2011-07-12 | 2014-10-23 | Rowan University | Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease |
US20150141491A1 (en) * | 2012-07-11 | 2015-05-21 | The University Of Birmingham | Therapeutic Targets for Alzheimer's Disease |
CN109576362A (en) * | 2018-12-28 | 2019-04-05 | 北京泱深生物信息技术有限公司 | Alzheimer diagnosis and treatment marker FAM170A |
Non-Patent Citations (2)
Title |
---|
JUAN LUIS FERNÁNDEZ-MARTÍNEZ等: "Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
KARINA HERN_ANDEZ-ORTEGA等: "Altered Machinery of Protein Synthesis in Alzheimer’s: From the Nucleolus to the Ribosome", 《BRAIN PATHOLOGY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114999656A (en) * | 2022-07-27 | 2022-09-02 | 苏州药明泽康生物科技有限公司 | Alzheimer disease risk assessment system and module |
CN114999656B (en) * | 2022-07-27 | 2023-01-03 | 苏州药明泽康生物科技有限公司 | Alzheimer disease risk assessment system and module |
CN117711616A (en) * | 2023-11-23 | 2024-03-15 | 北京爱思益普生物科技股份有限公司 | Alzheimer's prediction model establishment method and system based on gene expression data |
Also Published As
Publication number | Publication date |
---|---|
CN116219002A (en) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021176328A (en) | Epigenetic chromosome interaction | |
CN103781919A (en) | Microrna biomarkers indicative of alzheimer's disease | |
US20160327572A1 (en) | Biomarkers for Dementia and Dementia Related Neurological Disorders | |
WO2020244018A1 (en) | Small-scale schizophrenia biomarker combination, application thereof and metaphlan2 screening method therefor | |
CN113308539A (en) | Product for diagnosing alzheimer's disease | |
CN113528643A (en) | Biomarker related to depression, and diagnostic product and application thereof | |
CN112522412A (en) | Reagent and product for detecting biomarkers and application of reagent and product in diseases | |
CN111020020A (en) | Biomarker combination for schizophrenia, application thereof and metaplan 2 screening method | |
CN112522413A (en) | Biomarker for evaluating gastric cancer risk and application thereof | |
CN114875149A (en) | Application of reagent for detecting biomarkers in preparation of product for predicting gastric cancer prognosis | |
Chiou et al. | Multiregion transcriptomic profiling of the primate brain reveals signatures of aging and the social environment | |
CN115701286A (en) | Systems and methods for detecting risk of alzheimer's disease using non-circulating mRNA profiling | |
EP3294933A1 (en) | Systems and methods to predict autism before onset of behavioral symptoms and/or to diagnose autism | |
US20180171406A1 (en) | Identification of epigenetic biomarkers in the saliva of children with autism spectrum disorder | |
CN112795648A (en) | Gastric cancer diagnostic product | |
CN112538531A (en) | Product for detecting gastric cancer | |
CN112746107A (en) | Gastric cancer related biomarkers and their use in diagnosis | |
CN114438191B (en) | Application of hypoxia inducible factor 1 alpha as marker in diagnosis of depression recurrence | |
KR20240110613A (en) | Systems and methods for evaluating immunological peptide sequences | |
US12054779B2 (en) | Circulating miRNAs as biomarkers for diagnosis of mild cognitive impairment and Alzheimer's disease | |
CN112575089A (en) | Application of gene in diagnosis of gastric cancer | |
CN112680521A (en) | Product using gene as diagnostic marker and application thereof | |
CN113265462A (en) | Gene related to gastric cancer and application thereof | |
CN112725443A (en) | Biomarker combination and application thereof | |
CN112877417A (en) | Screening and application of polycystic ovarian syndrome intestinal flora biomarker |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210827 |